Paper Review Records
All Paper Review Records
16 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
38
days
Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors
Authors
Alejandro Falcón; Gregory M. Cote; Javier Molina-Cerrillo; Axel Le Cesne; Pedro Rocha; Bruno Bockorny; David Paez; Javier Martin-Broto; Sant P. Chawla; Sara Martinez; Carmen Kahatt; Vicente Alfaro; Mariano Siguero; Javier Jimenez; Ana Custodio; Vicente Alonso-Orduña; Carlos López; Attila Kollár; Juan José Soto-Castillo; Luis Paz-AresShow moreShow less
Affiliations
1. Medical Oncology Department, Hospital Universitario Virgen del Rocio, Seville, Spain; 2. Servicio de Oncología Médica, Hospital Universitario Virgen del Rocio, Seville, Spain; 3. Medical Oncology Department, Mass General Brigham Cancer Institute, Boston, USA; 4. Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain; 5. Medical Oncology Department, Institute Gustave Roussy, Villejuif, France; 6. Medical Oncology Department, Vall d’ Hebrón University Hospital, Barcelona, Spain; 7. Medical Oncology Department, Beth Israel Deaconess Medical Center, Boston, USA; 8. Medical Oncology Department, Sant Pau, CIBERER, Barcelona, Spain; 9. Medical Oncology Department, Fundación Jiménez Díaz University Hospital General de Villalba, and Instituto deInvestigacion Sanitaria Fundacion Jimenez Diaz (IIS/FJDUAM), Madrid, Spain; 10. Sarcoma Oncology Research Center, Santa Monica, USA; 11. Clinical R&D, Pharma Mar, Colmenar Viejo, Madrid, Spain; 12. Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain; 13. Medical Oncology Department, Hospital Universitario Miguel Servet, Saragossa, Spain; 14. Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, UNICAN, Santander, Spain; 15. Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; 16. Medical Oncology Department, START Madrid CIOCC, Hospital Universitario HM Sanchinarro, Madrid, Spain; 17. Medical Oncology Department, Hospital Universitario, Madrid, SpainShow moreShow less
34
days
Class-level DILI saturation and hERG-driven risk stratification among 2024–2025 FDA-approved kinase inhibitors: an in silico multi-platform safety analysis
Authors
Nihan Küçük Yılmaz; Veysel BaskınShow moreShow less
Affiliations
1. Department of Medical Pharmacology, Faculty of Medicine, Yalova University, Yalova, Turkey; 2. Department of Medical Pharmacology, Faculty of Medicine, Hitit University, Çorum, TurkeyShow moreShow less
34
days
Hedgehog Inhibitor and Paclitaxel: A Phase I Trial of the Oral Hedgehog inhibitor Taladegib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumours
Authors
Rosalind Glasspool; Sarah Patricia Blagden; Michelle Lockley; Elaine McCartney; Carol Evans; Fiona Thomson; Jennifer Brown; Laura Spiers; Chantevy Pou; Liz-Anne Lewsley; Iain A. McNeish; T.R. Jeffry EvansShow moreShow less
Affiliations
1. Beatson West of Scotland Cancer Centre and School of Cancer Sciences, University of Glasgow, Glasgow, UK; 2. Early Phase Clinical Trials Unit, Churchill Hospital, Oxford University Hospitals, Oxford, UK; 3. Centre for Cancer Centre for Cancer Evolution, Barts Cancer Institute, Queen Mary University of London, London, UK; 4. Cancer Division, University College London Hospital, London, UK; 5. Glasgow Oncology Clinical Trials Unit, University of Glasgow, Glasgow, UK; 6. The Translational Pharmacology & Immunology Laboratory, School of Cancer Sciences, University of Glasgow, Glasgow, UK; 7. Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UKShow moreShow less
37
days
Prostate cancer cells’ growth is decreased by novel MYC inhibitors
Authors
Bita Nickkholgh; Joseph McGrath; Sivanandane Sittadjody; Jay Chauhan; Kwan-Young Jung; Steven Fletcher; K. C. BalajiShow moreShow less
Affiliations
1. Wake Forest Institute for Regenerative Medicine (WFIRM), Wake Forest University School of Medicine, Winston-Salem, USA; 2. Department of Physiology-Pharmacology, Wake Forest University School of Medicine, Winston-Salem, USA; 3. Department of Urology, University of FL College of Medicine – Jacksonville, Jacksonville, USA; 4. Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, USAShow moreShow less
126
days
Spatial blueprint of colorectal cancer identifies Hypoxic CAF program that orchestrates Go-or-Grow decisions and predicts outcomes
Authors
Mingkai Chen; Juan Yang; Jin Wang; Guangrun Du; Lida ZhangShow moreShow less
Affiliations
1. Department of Gastroenterology, Fuwai Central China Cardiovascular Hospital, Zhengzhou, China; 2. Department of Gastroenterology, Zhengzhou Yihe Hospital Affiliated to Henan University, Zhengzhou, ChinaShow moreShow less
160
days
Recent progress of dendritic cell-derived exosomes in tumor immunotherapy
Authors
Baiyan Wang; Yirui Hu; Yujia Zhou; Qianqian Han; Yu Huang; Yuanhang Dong; Yike Zhang; Zixuan Guo; Xuan Zhang; Shuying FengShow moreShow less
Affiliations
1. Medical College, Henan University of Chinese Medicine, Zhengzhou, China; 2. Henan Engineering Research Center for Chinese Medicine Foods for Special Medical Purpose, Zhengzhou, ChinaShow moreShow less
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
